Lakefront Biotherapeutics NV
LKFT
$27.04
-$0.39-1.42%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 102.01% | 110.30% | 3,492.13% | -1,341.01% | -1,341.01% |
| Total Depreciation and Amortization | -91.63% | -- | -- | 112.11% | 112.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -267.75% | -283.40% | 80.11% | 219.08% | 219.08% |
| Change in Net Operating Assets | 88.42% | -83.45% | -1,482.91% | 18.51% | 18.51% |
| Cash from Operations | 68.48% | -133.74% | -1.23% | -72.66% | -72.66% |
| Capital Expenditure | 99.30% | 97.37% | 65.42% | -31.96% | -31.96% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 108.02% | -92.00% | 12.11% | -504.66% | -504.66% |
| Other Investing Activities | 728.24% | 9.14% | 17.59% | 45.56% | 45.56% |
| Cash from Investing | 36.55% | -20.87% | 24.72% | 19.33% | 19.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -78.00% | 49.55% | 74.75% | 43.61% | 43.61% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -560.12% | 44.99% | 70.51% | 40.53% | 40.53% |
| Foreign Exchange rate Adjustments | 436.00% | 158.76% | -211.87% | -513.13% | -513.13% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 291.08% | -152.41% | 109.48% | -3,576.17% | -3,576.17% |